Anti-angiogenic strategies in glioblastoma;Stratégies anti-angiogéniques dans le glioblastome

Revue Neurologique

Volumn 167, Issue 10, 2011, Pages 662-667

  Guillamo, J S ^a,b  

^a CHU CÔTE DE NACRE   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

Angiogenesis; Anti angiogenic; Glioblastoma; Recurrence; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; ARTICLE; GLIOBLASTOMA; HUMAN; PHENOTYPE; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR ESCAPE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN EDEMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81955161113     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2011.07.008     Document Type: Article

References (33)

1. T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, and E. Gerstner Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2010 2817 2823
2. T.T. Batchelor, A.G. Sorensen, E. di Tomaso, W.T. Zhang, D.G. Duda, and K.S. Cohen AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 (Pubitemid 46075199)
3. A. Behin, K. Hoang-Xuan, A.F. Carpentier, and J.Y. Delattre Primary brain tumours in adults Lancet 361 2003 323 331 (Pubitemid 36126198)
4. D. Bose, F. Meric-Bernstam, W. Hofstetter, D.A. Reardon, K.T. Flaherty, and L.M. Ellis Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care Lancet Oncol 11 2010 373 382
5. K.M. Cook, and W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA Cancer J Clin 60 2010 222 243
6. S. de Bouard, and J.S. Guillamo Angiogenesis and anti-angiogenic strategies for glioblastoma Bull Cancer 92 2005 360 372
7. S. De Bouard, J.S. Guillamo, C. Christov, N. Lefevre, P. Brugieres, and E. Gola Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin Hum Gene Ther 14 2003 883 895 (Pubitemid 36693797)
8. H.A. Fine, W.D. Figg, K. Jaeckle, P.Y. Wen, A.P. Kyritsis, and J.S. Loeffler Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas J Clin Oncol 18 2000 708 715 (Pubitemid 30106600)
9. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
10. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
11. J.S. Guillamo, F. Lisovoski, C. Christov, C. Le Guerinel, G.L. Defer, and M. Peschanski Migration pathways of human glioblastoma cells xenografted into the immunosuppressed rat brain J Neurooncol 52 2001 205 215 (Pubitemid 33638519)
12. S. Guiu, S. Taillibert, O. Chinot, L. Taillandier, J. Honnorat, and P.Y. Dietrich Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study Rev Neurol (Paris) 164 2008 588 594 (Pubitemid 351902232)
13. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
14. A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.Y. Delattre Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors Oncologist 13 2008 978 992
15. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
16. R.K. Jain, E. di Tomaso, D.G. Duda, J.S. Loeffler, A.G. Sorensen, and T.T. Batchelor Angiogenesis in brain tumours Nat Rev Neurosci 8 2007 610 622 (Pubitemid 47093931)
17. P. Kleihues, D.N. Louis, B.W. Scheithauer, L.B. Rorke, G. Reifenberger, and P.C. Burger The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 2002 215 225 [discussion 226-9] (Pubitemid 34212595)
18. A. Lai, E. Filka, B. McGibbon, P.L. Nghiemphu, C. Graham, and W.H. Yong Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 2008 1372 1380
19. B. Neyns, J. Sadones, C. Chaskis, M. Dujardin, H. Everaert, and S. Lv Phase II study of sunitinib malate in patients with recurrent high-grade glioma J Neurooncol 103 2011 491 501
20. A.D. Norden, J. Drappatz, and P.Y. Wen Novel anti-angiogenic therapies for malignant gliomas Lancet Neurol 7 2008 1152 1160
21. A.D. Norden, G.S. Young, K. Setayesh, A. Muzikansky, R. Klufas, and G.L. Ross Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 2008 779 787
22. W.B. Pope, A. Lai, P. Nghiemphu, P. Mischel, and T.F. Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 2006 1258 1260 (Pubitemid 43739717)
23. W. Risau Mechanisms of angiogenesis Nature 386 1997 671 674 (Pubitemid 27193480)
24. B.J. Scott, E.C. Quant, M.B. McNamara, P.A. Ryg, T.T. Batchelor, and P.Y. Wen Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors Neuro Oncol 12 2010 603 607
25. D. Shweiki, A. Itin, D. Soffer, and E. Keshet Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 845
26. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
27. R. Stupp, M.E. Hegi, B. Neyns, R. Goldbrunner, U. Schlegel, and P.M. Clement Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 2712 2718
28. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
29. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J.M. Dowell, D.A. Reardon, and J.A. Quinn Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 2007 1253 1259 (Pubitemid 46424067)
30. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
31. P.Y. Wen, D.R. Macdonald, D.A. Reardon, T.F. Cloughesy, A.G. Sorensen, and E. Galanis Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
32. A. Wick, N. Dorner, N. Schafer, S. Hofer, S. Heiland, and D. Schemmer Bevacizumab does not increase the risk of remote relapse in malignant glioma Ann Neurol 69 2011 586 592
33. W. Wick, M. Weller, M. van den Bent, and R. Stupp Bevacizumab and recurrent malignant gliomas: a European perspective J Clin Oncol 28 2010 e188 e189 [author reply e190-2]